Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate

A method for treating cancer in a subject in need thereof, the method comprising:

• (a) detecting a cancer that is associated with one or more of overexpression, activation, amplification, and mutation of a Trk kinase in a subject;
• and
• (b) administering to the subject a therapeutically effective amount of a crystalline form (I—HS) having the formula:
• wherein the crystalline form is characterized by having XRPD diffraction peaks (2θ degrees) at 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2.

A method for treating cancer in a subject in need thereof, the method comprising:

• (a) detecting a cancer mediated by a Trk kinase in a subject;
• and
• (b) administering to the subject a therapeutically effective amount of a crystalline form (I—HS) having the formula:
• wherein the crystalline form is characterized by having XRPD diffraction peaks (2θ degrees) at 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2.

A method of treating a subject comprising:

• (a) performing an assay on a sample obtained from the subject to determine that the subject has dysregulation of a NTRK gene, a Trk protein, or expression or level of the same;
• and
• (b) administering to the subject determined to have dysregulation of a NTRK gene, a Trk protein, or expression or activity, or level of the same a therapeutically effective amount of a crystalline form (I—HS) having the formula:
• wherein the crystalline form is characterized by having XRPD diffraction peaks (2θ degrees) at 18.4±0.2, 20.7±0.2, 23.1±0.2, and 24.0±0.2.